

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

**VOLUNTARY ANNOUNCEMENT
APPOINTMENT OF MR. GIORGIO GOBBI AS VICE PRESIDENT,
GLOBAL THERAPY DEVELOPMENT OF ANGIOCARE**

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Mr. Giorgio Gobbi (“**Mr. Gobbi**”), a former senior executive at both Medtronic and ReCor Medical, has joined Shanghai AngioCare Medical Technology Co., Ltd. (“**AngioCare**”), a non-wholly owned subsidiary of the Company, as Vice President, Global Therapy Development, and will be fully responsible for the global therapy development of the Iberis® Renal Denervation (“**RDN**”) System.

Background of Mr. Gobbi

Mr. Gobbi holds a Doctor of Medicine (M.D.) degree and has over two decades of experience in the cardiovascular and metabolic disease fields, combining a solid clinical practice background with proven capabilities in global medical strategy and therapy development at leading multinational medical device companies. In the early stage of his career, he served as a clinician specialising in the clinical diagnosis and treatment of chronic diseases such as hypertension and metabolic syndrome, gaining deep insight into the core needs of cardiologists for innovative therapies.

Upon entering the medical device industry, Mr. Gobbi successively served at Ardian, Medtronic and ReCor Medical, all of which are benchmark companies in the global RDN field. As one of the earliest industry leaders in the field of renal denervation, he has personally experienced the full development cycle of RDN, from technological exploration, industry debate and evidence-based iteration through to global clinical adoption, and possesses highly mature operating experience in the building of clinical evidence and the global promotion of therapies.

Mr. Gobbi also publicly expressed his expectation and confidence in joining AngioCare on his personal professional social media platform, LinkedIn, stating:

“I am very grateful to be joining AngioCare at such an exciting and critical stage. Going forward, I will fully leverage decades of experience in the field of renal denervation (RDN), and am committed to building deeper and more meaningful collaborations with clinicians and key opinion leaders (KOLs) in the global cardiovascular field, so as to jointly advance the clinical adoption of this innovative therapy with significant potential.”

Roles and Responsibilities

Upon joining AngioCare, Mr. Gobbi will be primarily responsible for the global therapy development of the Iberis® RDN System, including global key opinion leader academic collaboration, the establishment of expert advisory boards, the strategic planning of post-market global clinical programmes, and the standardisation and regulation of the international training system.

This appointment coincides with the acceleration of AngioCare’s globalisation strategy. At present, AngioCare is working with Biosensors International, an internationally renowned cardiovascular interventional device company, to comprehensively advance the hypertension management and commercialisation of the Iberis® RDN System in multiple overseas regions. Going forward, Mr. Gobbi will work closely with the team and partners to advance overseas clinical research, the accumulation of evidence-based data and regulatory registration in various countries, and continue to expand into overseas markets such as Europe, the Asia-Pacific region, the Middle East and Latin America, so as to build a global commercialisation operating system centred on clinical innovation.

The Board believes that Mr. Gobbi's extensive industry experience and professional expertise will contribute significantly to the future growth and development of both the Company and AngioCare. The Board would like to extend its warmest welcome to Mr. Gobbi on his appointment.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that Iberis® RDN system will be ultimately developed and marketed successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive Director

Shanghai, the People's Republic of China, September 7, 2026

As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive Director, Mr. Yunqing WANG and Ms. Peili WANG as executive Directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive Directors.